These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 28923212)

  • 1. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
    Fessas P; Lee H; Ikemizu S; Janowitz T
    Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
    Tan S; Zhang H; Chai Y; Song H; Tong Z; Wang Q; Qi J; Wong G; Zhu X; Liu WJ; Gao S; Wang Z; Shi Y; Yang F; Gao GF; Yan J
    Nat Commun; 2017 Feb; 8():14369. PubMed ID: 28165004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immune checkpoints in lymphoma.
    Ansell SM
    Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
    Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
    PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
    Nastoupil LJ; Neelapu SS
    Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.
    Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
    Sci Rep; 2018 Jan; 8(1):1840. PubMed ID: 29382901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biophysical and Immunological Characterization and
    Hutchins B; Starling GC; McCoy MA; Herzyk D; Poulet FM; Dulos J; Liu L; Kang SP; Fayadat-Dilman L; Hsieh M; Andrews CL; Ayanoglu G; Cullen C; Malefyt RW; Kastelein RA; Saux SL; Lee J; Li S; Malashock D; Sadekova S; Soder G; van Eenennaam H; Willingham A; Yu Y; Streuli M; Carven GJ; van Elsas A
    Mol Cancer Ther; 2020 Jun; 19(6):1298-1307. PubMed ID: 32229606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy.
    Kalim M; Iqbal Khan MS; Zhan J
    Chem Biol Drug Des; 2020 Jun; 95(6):552-566. PubMed ID: 32166894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.
    Wang GX; Guo LQ; Gainor JF; Fintelmann FJ
    AJR Am J Roentgenol; 2017 Sep; 209(3):567-575. PubMed ID: 28657846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
    Lee JY; Lee HT; Shin W; Chae J; Choi J; Kim SH; Lim H; Won Heo T; Park KY; Lee YJ; Ryu SE; Son JY; Lee JU; Heo YS
    Nat Commun; 2016 Oct; 7():13354. PubMed ID: 27796306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.
    Almutairi AR; Alkhatib N; Martin J; Babiker HM; Garland LL; McBride A; Abraham I
    Crit Rev Oncol Hematol; 2019 Oct; 142():16-25. PubMed ID: 31326706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
    Naing A; Wong DJ; Infante JR; Korn WM; Aljumaily R; Papadopoulos KP; Autio KA; Pant S; Bauer TM; Drakaki A; Daver NG; Hung A; Ratti N; McCauley S; Van Vlasselaer P; Verma R; Ferry D; Oft M; Diab A; Garon EB; Tannir NM
    Lancet Oncol; 2019 Nov; 20(11):1544-1555. PubMed ID: 31563517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in renal cell carcinoma.
    Michel Ortega RM; Drabkin HA
    Expert Opin Biol Ther; 2015 Jul; 15(7):1049-60. PubMed ID: 26038957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.
    Prasad V; Kaestner V
    Semin Oncol; 2017 Apr; 44(2):132-135. PubMed ID: 28923211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.